Oncology Nursing News Staff

Julie Elliott, MS, PA-C, reviewed clinical trial data, compared efficacy across third-line regimens, and discussed how real-world outcomes align across third-line treatment options.

An updated post hoc analysis showed that imetelstat nearly doubled overall survival compared with best available therapy in patients with JAK inhibitor–relapsed or refractory myelofibrosis.

The phase 2 ARACOG study is the first head-to-head randomized comparison of cognitive effects between the 2 androgen receptor pathway inhibitors.

Studies to be presented at the 2026 ASCO Annual Meeting examine GLP-1 receptor agonists in relation to cancer progression, survival, and immune-related adverse events.

A study conducted by SEER and Medicare revealed that nearly half of older patients diagnosed with metastatic non-small cell lung cancer never received systemic therapy.

FDA expands Alpha DaRT IMPACT trial to 40 patients, adding gemcitabine and nab-paclitaxel cohort in pancreatic cancer.

FDA grants fast track designation to lunresertib plus zedoresertib for genomic-defined platinum-resistant ovarian cancer following phase 1 data.

Ozekibart plus FOLFIRI demonstrated a 20% response rate and 5.5-month progression-free survival in heavily pretreated colorectal cancer.

LITESPARK-012 failed to improve OS or PFS in advanced renal cell carcinoma, reinforcing pembrolizumab plus lenvatinib as a first-line standard.

FDA grants Priority Review to enfortumab vedotin plus pembrolizumab in MIBC, showing improved survival and reduced recurrence risk in phase 3 EV-304 trial.

Learn about the rising cancer burden, the importance of patient navigation, and strategies to close the equity gap in low-resource settings.

The FDA has granted full approval to brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma based on ZUMA-2 data.

The CHRONOS study highlights a 29% 12-month survival rate for third-line GI-aGvHD, underscoring an urgent need for standardized therapies after ruxolitinib failure.

The FDA has granted Fast Track designation to the FRα-targeting ADC ZW191 as a potential treatment for patients with for platinum-resistant ovarian cancer.

Natalia Neparidze, MD, discusses subcutaneous daratumumab safety, MRD as a clinical endpoint, and emerging therapies for multiple myeloma management.

A physician, physician assistant, and nurse practitioner share perspectives on integrative medicine in oncology.

The NCCN has added sacituzumab govitecan with pembrolizumab as a category 1 preferred regimen for patients with PD-L1–postive TNBC.

Data presented at the APOS Annual Conference highlighted sexual function issues and a web-based intervention for AYA cancer survivors.

Patients younger than 40 experience higher rates of CINV and more commonly use marijuana, diet changes, and other methods to manage symptoms.

What should oncology nurses and advanced practice providers understand about GLP-1 RAs in the care of patients with breast cancer?

Explore safety and efficacy findings from KEYNOTE-B15/EV-304, LITESPARK-011, and more from the ASCO Genitourinary Cancers Symposium.

WVU Medicine has begun treating patients in the first clinical trial to explore the use of subcutaneous blinatumomab in patients with CD19-positive MPAL.

FDA fast-tracks trispecific IBI3003, reviews iberdomide combo, and expands Yescarta use.

The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment.

A device delivering tumor treating fields has been approved for concurrent treatment with gemcitabine and nab-paclitaxel for patients with LA-PAC.

Patients with NRG1 fusion-positive cholangiocarcinoma who received zenocutuzumab had a favorable response rate in the phase 1/2 eNRGy trial.